RBC Capital Defending on Axsome Therapeutics (AXSM)

March 13, 2026 6:02 AM

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $22.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found